Cannabis stock Cronos soars 24% as Altria takes major stake

This post was originally published on this site

Shares of Canada’s Cronos Corp. rocketed more than 24% Friday, after Altria Group Inc. agreed to take a major stake in the company and become its exclusive partner in the cannabis sector as new markets for medical and recreational weed open around the world.

The news sparked a rally in the broader sector, which has been expecting moves by big tobacco, given the overlap of growing and harvesting with the burgeoning weed industry. Cronos CRON, +20.14% CRON, +22.39%  had disclosed early talks with Altria MO, +1.99%  and analysts were expecting the owner of Philip Morris PM, +0.02%  and its Marlboro brand to make a strategic move as it struggles with regulatory challenges and changing consumer behavior in its traditional market.

Corona beer maker Constellation Brands Inc. STZ, +0.06%  caused a stir when it placed $4 billion in another Canadian company, Canopy Growth Corp. CGC, +3.16% WEED, +4.21%  in August and said it may develop a line of cannabis-infused drinks for the Canadian market next year. Canada fully legalized cannabis for adult recreational use in October. The U.S. market is more challenging for cannabis companies, as the substance remains illegal at the federal level, where it is still classified as a Schedule 1 drug, putting it in the same category as heroin and cocaine. That means that companies operating in the states that have legalized medical or recreational cannabis through the ballot box are not able to have bank accounts with federally-backed institutions.

Altria is investing C$2.4 billion ($1.8 billion) to acquire a 45% stake in Cronos and will also receive warrants that, if exercised, would increase that stake to 55% and give Cronos another C$1.4 billion in proceeds. Altria is paying C$16.25 per Cronos share, a 41.5% premium over its 10-day volume-weighted average price on the Toronto Stock Exchange on November 30, the last day before Cronos disclosed the Altria talks.

Read now: Marijuana producer Aphria’s stock rebounds after second short-seller report

Also: How ‘peak good news’ for marijuana stocks may undermine investors

“The proceeds from Altria’s investment will enable us to more quickly expand our global infrastructure and distribution footprint, while also increasing investments in R&D and brands that resonate with our consumers,” Cronos Chief Executive Mike Gorenstein said in a statement.

Wells Fargo analyst Bonnie Herzog said the news was “very positive” as it expands Altria’s total addressable market. “Overall, we applaud MO’s decision to pivot fast and to move into a new adjacent category (cannabis) that is complimentary to its core tobacco business,” she said, reiterating her outperform rating on Altria stock.

Short seller Citron Research weighed in too.

Altria is expected to bring its expertise in regulation, government affairs, and compliance, as well as technical expertise in growing, harvesting, manufacturing and marketing and supply chain management to Cronos.

Don’t miss: Marijuana investors have a new reason to believe they will get rich

Cronos has partnerships with Ginkgo Bioworks to develop cannabinoids, the ingredients found in cannabis, and with Technion Research and Development Foundation for cannabinoid skin-care treatments. Altria will have the right to nominate four directors, including one independent director, to serve on the Cronos board, which will expanded to seven directors from five as part of the deal.

The transaction is expected to close in the first half of 2019.

Separately, Altria said it is discontinuing its MarkTen and Green Smoke e-vape products, along with Verve oral nicotine-containing products in response to regulatory restrictions that will hamper its effort to improve their financial performance.

Read now: Canada’s struggle to supply legal weed described as ‘national shortage’ that could last months

Don’t miss: The collapse of this cannabis stock offers a valuable lesson to every investor

To see all of MarketWatch’s coverage of the cannabis sector, click here.

The tobacco giant said it will refocus its efforts on reduced-risk tobacco product opportunities.

“We do not see a path to leadership with these particular products and believe that now is the time to refocus our resources,” Chief Executive Howard Willard said in a statement. Altria is expecting to book a roughly $200 million pretax charge in the fourth quarter, most of which will be a non-cash asset impairment charge.

Wells Fargo’s Herzog welcomed that move too and said she expects an announcement to acquire a stake in e-cigarette maker Juul “very soon”.

Read now: Altria may be adding a Juul to its crown if talks with e-cigarette company end in deal

Elsewhere in the cannabis sector, Green Organic Dutchman Holdings TGODF, +13.84% TGOD, +12.90%  was up 10.5%, Aleafia Health Inc. ALEAF, +13.67%  was up 5.6% and Aurora Cannabis Inc. ACB, +7.39% ACB, +8.79%  was up 5.4%.

Canopy Growth was up 3.75, Tilray Inc. TLRY, +3.24%  was up 1.2% and Hexo Corp. HEXO, +5.38%  was up 3.7%.

The ETFMG Alternative Harvest ETF MJ, +5.93%  was up about 7% and the Horizons Marijuana Life Sciences ETF HMMJ, +6.25%  was up 5.5%.

Altria was up 2.2%, but is down 22% in 2018, while the Dow Jones Industrial Average DJIA, -1.67%  has gained 1% and the S&P 500 SPX, -1.55%  has gained 0.9%.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.